相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。ROS1-dependent cancers - biology, diagnostics and therapeutics
Alexander Drilon et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2021)
Spectrum of Mechanisms of Resistance to Crizotinib and Lorlatinib in ROS1 Fusion-Positive Lung Cancer
Jessica J. Lin et al.
CLINICAL CANCER RESEARCH (2021)
Clinical and molecular factors that impact the efficacy of first-line crizotinib in ROS1-rearranged non-small-cell lung cancer: a large multicenter retrospective study
Yongchang Zhang et al.
BMC MEDICINE (2021)
MAPK Pathway Alterations Correlate with Poor Survival and Drive Resistance to Therapy in Patients with Lung Cancers Driven by ROS1 Fusions
Hiroki Sato et al.
CLINICAL CANCER RESEARCH (2020)
Detection of Nonreciprocal/Reciprocal ALK Translocation as Poor Predictive Marker in Patients With First -Line Crizotinib-Treated ALK-Rearranged NSCLC
Yongchang Zhang et al.
JOURNAL OF THORACIC ONCOLOGY (2020)
Focus on ROS1-Positive Non-Small Cell Lung Cancer (NSCLC): Crizotinib, Resistance Mechanisms and the Newer Generation of Targeted Therapies
Alberto D'Angelo et al.
CANCERS (2020)
Molecular Analysis of Plasma From Patients With ROS1-Positive NSCLC
Ibiayi Dagogo-Jack et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Unique genetic profiles from cerebrospinal fluid cell-free DNA in leptomeningeal metastases of EGFR-mutant non-small-cell lung cancer: a new medium of liquid biopsy
Y. S. Li et al.
ANNALS OF ONCOLOGY (2018)
Resistance Mechanisms to Targeted Therapies in ROS1(+) and ALK(+) Non-small Cell Lung Cancer
Caroline E. McCoach et al.
CLINICAL CANCER RESEARCH (2018)
Appearance of a BRAF Mutation Conferring Resistance to Crizotinib in Non-Small Cell Lung Cancer Harboring Oncogenic ROS1 Fusion
Junko Watanabe et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
The Incidence of Brain Metastases in Stage IV ROS1-Rearranged Non-Small Cell Lung Cancer and Rate of Central Nervous System Progression on Crizotinib
Tejas Patil et al.
JOURNAL OF THORACIC ONCOLOGY (2018)
Recent Advances in Targeting ROS1 in Lung Cancer
Jessica J. Lin et al.
JOURNAL OF THORACIC ONCOLOGY (2017)
Crizotinib-Resistant ROS1 Mutations Reveal a Predictive Kinase Inhibitor Sensitivity Model for ROS1- and ALK-Rearranged Lung Cancers
Francesco Facchinetti et al.
CLINICAL CANCER RESEARCH (2016)
PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations
Helen Y. Zou et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
Activation of RAS family members confers resistance to ROS1 targeting drugs
Marilisa Cargnelutti et al.
ONCOTARGET (2015)
Case 16-2013: A Girl with Irritability, Hypersomnia, and Somatic Symptoms
Linda Shavit et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
分享论文
